Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2010

Open Access 01-12-2010 | Short communication

Characterization of the role of the tumor marker Nup88 in mitosis

Authors: Chieko Hashizume, Hiroshi Nakano, Kimihisa Yoshida, Richard W Wong

Published in: Molecular Cancer | Issue 1/2010

Login to get access

Abstract

Nuclear pore complexes are massive multiprotein channels responsible for traffic between the nucleus and cytoplasm, and are composed of approximately 30 proteins, termed nucleoporins (Nup). Our recent studies indicated that the nucleoporins Rae1 and Tpr play critical roles in maintaining the spindle bipolarity during cell division. In the present study, we found that another nucleoporin, Nup88, was localized on the spindles together with Nup214 during mitosis. Nup88 expression is linked to the progression of carcinogenesis, Nup88 has been proposed as a tumor marker. Overexpression of Nup88 enhanced multinucleated cell formation. RNAi-mediated knockdown of Nup88 disrupted Nup214 expression and localization and caused multipolar spindle phenotypes. Our data indicate that proper expression of Nup88 is critical for preventing aneuploidy formation and tumorigenesis.
Appendix
Available only for authorised users
Literature
1.
Wong RW: Interaction between Rae1 and cohesin subunit SMC1 is required for proper spindle formation. Cell Cycle. 2010, 9: 1-3.CrossRef
2.
Wong RW, Blobel G: Cohesin subunit SMC1 associates with mitotic microtubules at the spindle pole. Proc Natl Acad Sci USA. 2008, 105: 15441-15445. 10.1073/pnas.0807660105PubMedCentralCrossRefPubMed
3.
Wong RW, Blobel G, Coutavas E: Rae1 interaction with NuMA is required for bipolar spindle formation. Proc Natl Acad Sci USA. 2006, 103: 19783-19787. 10.1073/pnas.0609582104PubMedCentralCrossRefPubMed
4.
Nakano H, Funasaka T, Hashizume C, Wong RW: Nucleoporin Tpr associates with dynein complex preventing chromosome lagging formation during mitosis. J Biol Chem. 2010, 285: 10841-10849. 10.1074/jbc.M110.105890PubMedCentralCrossRefPubMed
5.
Terry LJ, Shows EB, Wente SR: Crossing the nuclear envelope: hierarchical regulation of nucleocytoplasmic transport. Science. 2007, 318: 1412-1416. 10.1126/science.1142204CrossRefPubMed
6.
Tran EJ, Wente SR: Dynamic nuclear pore complexes: life on the edge. Cell. 2006, 125: 1041-1053. 10.1016/j.cell.2006.05.027CrossRefPubMed
7.
Lim RY, Ullman KS, Fahrenkrog B: Biology and biophysics of the nuclear pore complex and its components. Int Rev Cell Mol Biol. 2008, 267: 299-342. full_textPubMedCentralCrossRefPubMed
8.
Guttinger S, Laurell E, Kutay U: Orchestrating nuclear envelope disassembly and reassembly during mitosis. Nat Rev Mol Cell Biol. 2009, 10: 178-191. 10.1038/nrm2641CrossRefPubMed
9.
Blower MD, Nachury M, Heald R, Weis K: A Rae1-containing ribonucleoprotein complex is required for mitotic spindle assembly. Cell. 2005, 121: 223-234. 10.1016/j.cell.2005.02.016CrossRefPubMed
10.
Orjalo AV, Arnaoutov A, Shen Z, Boyarchuk Y, Zeitlin SG, Fontoura B, Briggs S, Dasso M, Forbes DJ: The Nup107-160 nucleoporin complex is required for correct bipolar spindle assembly. Mol Biol Cell. 2006, 17: 3806-3818. 10.1091/mbc.E05-11-1061PubMedCentralCrossRefPubMed
11.
Galy V, Askjaer P, Franz C, Lopez-Iglesias C, Mattaj IW: MEL-28, a novel nuclear-envelope and kinetochore protein essential for zygotic nuclear-envelope assembly in C. elegans. Curr Biol. 2006, 16: 1748-1756. 10.1016/j.cub.2006.06.067CrossRefPubMed
12.
Belgareh N, Rabut G, Bai SW, van Overbeek M, Beaudouin J, Daigle N, Zatsepina OV, Pasteau F, Labas V, Fromont-Racine M: An evolutionarily conserved NPC subcomplex, which redistributes in part to kinetochores in mammalian cells. J Cell Biol. 2001, 154: 1147-1160. 10.1083/jcb.200101081PubMedCentralCrossRefPubMed
13.
Salina D, Enarson P, Rattner JB, Burke B: Nup358 integrates nuclear envelope breakdown with kinetochore assembly. J Cell Biol. 2003, 162: 991-1001. 10.1083/jcb.200304080PubMedCentralCrossRefPubMed
14.
Mishra RK, Chakraborty P, Arnaoutov A, Fontoura BM, Dasso M: The Nup107-160 complex and gamma-TuRC regulate microtubule polymerization at kinetochores. Nat Cell Biol. 2010, 12: 164-169. 10.1038/ncb2016PubMedCentralCrossRefPubMed
15.
Chakraborty P, Seemann J, Mishra RK, Wei JH, Weil L, Nussenzveig DR, Heiber J, Barber GN, Dasso M, Fontoura BM: Vesicular stomatitis virus inhibits mitotic progression and triggers cell death. EMBO Rep. 2009, 10: 1154-1160. 10.1038/embor.2009.179PubMedCentralCrossRefPubMed
16.
17.
Bernad R, Engelsma D, Sanderson H, Pickersgill H, Fornerod M: Nup214-Nup88 nucleoporin subcomplex is required for CRM1-mediated 60 S preribosomal nuclear export. J Biol Chem. 2006, 281: 19378-19386. 10.1074/jbc.M512585200CrossRefPubMed
18.
Fornerod M, van Deursen J, van Baal S, Reynolds A, Davis D, Murti KG, Fransen J, Grosveld G: The human homologue of yeast CRM1 is in a dynamic subcomplex with CAN/Nup214 and a novel nuclear pore component Nup88. EMBO J. 1997, 16: 807-816. 10.1093/emboj/16.4.807PubMedCentralCrossRefPubMed
19.
Bernad R, Velde van der H, Fornerod M, Pickersgill H: Nup358/RanBP2 attaches to the nuclear pore complex via association with Nup88 and Nup214/CAN and plays a supporting role in CRM1-mediated nuclear protein export. Mol Cell Biol. 2004, 24: 2373-2384. 10.1128/MCB.24.6.2373-2384.2004PubMedCentralCrossRefPubMed
20.
Gould VE, Orucevic A, Zentgraf H, Gattuso P, Martinez N, Alonso A: Nup88 (karyoporin) in human malignant neoplasms and dysplasias: correlations of immunostaining of tissue sections, cytologic smears, and immunoblot analysis. Hum Pathol. 2002, 33: 536-544. 10.1053/hupa.2002.124785CrossRefPubMed
21.
Martinez N, Alonso A, Moragues MD, Ponton J, Schneider J: The nuclear pore complex protein Nup88 is overexpressed in tumor cells. Cancer Res. 1999, 59: 5408-5411.PubMed
22.
Gould VE, Martinez N, Orucevic A, Schneider J, Alonso A: A novel, nuclear pore-associated, widely distributed molecule overexpressed in oncogenesis and development. Am J Pathol. 2000, 157: 1605-1613.PubMedCentralCrossRefPubMed
Metadata
Title
Characterization of the role of the tumor marker Nup88 in mitosis
Authors
Chieko Hashizume
Hiroshi Nakano
Kimihisa Yoshida
Richard W Wong
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2010
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-9-119

Other articles of this Issue 1/2010

Molecular Cancer 1/2010 Go to the issue

Research

mTOR signaling is activated by FLT3 kinase and promotes survival of FLT3- mutated acute myeloid leukemia cells

Short communication

VHZ is a novel centrosomal phosphatase associated with cell growth and human primary cancers

Research

The mitochondria-independent cytotoxic effect of nelfinavir on leukemia cells can be enhanced by sorafenib-mediated mcl-1 downregulation and mitochondrial membrane destabilization

Research

IGFBP-rP1, a potential molecule associated with colon cancer differentiation

Research

NOTCH2 in breast cancer: association of SNP rs11249433 with gene expression in ER-positive breast tumors without TP53 mutations

Research

Krüppel-like factor 5 is a crucial mediator of intestinal tumorigenesis in mice harboring combined Apc Min and KRASV 12mutations
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits